Innovating Works

PHOENIX

Financiado
NANOMEDICINE FOR ORGAN TRANSPLANTATION TOLERANCE (PHOENIX)
PROBLEM: Today, organ transplant medicine is limited by life-long immunosuppression and vulnerability to infections, malignancies and cardiovascular diseases, and by a 20% rate of long-term graft failure. SOLUTION: PHOENIX reprog... PROBLEM: Today, organ transplant medicine is limited by life-long immunosuppression and vulnerability to infections, malignancies and cardiovascular diseases, and by a 20% rate of long-term graft failure. SOLUTION: PHOENIX reprograms the local immune micro-environment around a graft organ, inducing long-term transplant tolerance without broader systemic immunosuppression. FOUNDATIONS: Our expert teams have already discovered novel peptide-MHC complex-based nanomedicines for the treatment of autoimmune diseases. This project will transform, deploy and validate this nano-technology platform for transplant medicine. We have unique expertise in kidney and liver murine transplant models as well as liver transplantation in pigs and have established a molecular engineering pipeline for immune-protein synthesis to enable future clinical translation. Extensive clinical-trial expertise will enable us to progress efficiently from this project towards the clinic. WORKPLAN: We are designing and building a unique nanomedicine which delivers ubiquitous or self-antigens - common to all humans – that will redirect the host immune response against the graft toward regulation and tolerance development. These medicines will be demonstrated in murine and porcine models, laying the foundation for human clinical trials immediately post-project. SUMMARY: This project combines innovative multi-disciplinary approaches, building on a proven foundation, to deliver a novel therapy which will have a transformative positive effect on organ transplant patients and healthcare. ver más
31/03/2026
IRFMN
5M€
Duración del proyecto: 36 meses Fecha Inicio: 2023-03-14
Fecha Fin: 2026-03-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-14
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 5M€
Líder del proyecto
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEG... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5